1.    US Department of Health and Human Services. Guidelines for the Use of Antirretroviral Agents in HIV-1-infected Adults and  Adolescents. 10 October 2006. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed 28 February 2007.

2. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society. JAMA. 2006;296:827-843.

3. Datos en archivo  MSD México

4. Hazuda DJ. Inhibitors of human immunodeficiency virus type I integration. Curr Opin HIV AIDS. 2006;1:212-217.

5. Cahn P, Sued O. Raltegravir: a new antirretroviral class for salvage therapy. Lancet. 2007;369:1235-1236.

6. Lataillade M, Kozal MJ. The hunt for integrase inhibitors. AIDS Patient Care STDs. 2006;20:489-501.

7. Markowitz M, Morales-Ramirez JO, Nguyen B-Y, et al. Antirretroviral activity, pharmacokinetics, and tolerability of MK- 0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naïve HIV-1- infected individuals. J  Acquir Immune Defi c Syndr. 2006;43:509-515.

8. Grinsztejn B, Nguyen B-Y, Katlama C, et al. Safety and effi cacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multi drug-resistant virus: a phase II randomized controlled trial. Lancet. 2007;369:1261- 1269.